This article first appeared on GuruFocus .
-
Group Revenue:EUR2.04 billion in Q3 2026; EUR5.614 billion through nine months, up 4.6% at constant currency; Q3 growth accelerated to 8.4%.
-
Biopharma Revenue:Grew 10.3% in Q3 at constant currency, leading group growth.
-
Immunoglobulin (IG) Revenue:Up 11.3% in Q3 and 12.3% year-to-date at constant currency.
-
Subcutaneous IG Revenue:Up 40.3% in Q3; 25.6% year-to-date growth.
-
Alpha-1 & Specialty Proteins Revenue:Up 18.2% in Q3; 4.6% year-to-date, supported by Biotest contribution.
-
Albumin Revenue:Declined 13.2% in Q3 and 13.9% year-to-date at constant currency, driven by China market conditions.
-
Diagnostics Revenue:Down 7% through nine months due to dissolution of the Grifols Ortho joint business; underlying growth of 2.3% excluding this effect.
-
Gross Margin:39.6% in Q3; 38% through nine months.
-
Adjusted EBITDA:EUR538 million in Q3 (up 9.8%); EUR1.392 billion through nine months (up 5%).
-
Adjusted EBITDA Margin:26.4% in Q3 (up 60 bps); 24.8% through nine months (up 30 bps); full-year guidance of 25%.
-
Group Profit:EUR390 million through nine months, up 28.4% year on year.
-
Free Cash Flow (pre-M&A):EUR298 million through nine months, up 59% (EUR110 million) year on year; conversion above 20% of EBITDA.
-
Net Leverage:Total net leverage at 3.98x; secured net leverage at 2.5x.
-
Liquidity:EUR2.14 billion, over three times the September 2024 level.
-
Dividend:2026 interim dividend of EUR0.15 per share, payable early December 2026.
-
Egypt Plasma Collection:Monthly volumes nearly doubled since start of year; on track for ~1 million liters in 2026; 18 collection centers today, expanding to 20 by Q1 2027.
-
FX Impact:Year-to-date headwind of over 300 bps to reported revenue growth; mild tailwind in Q3.
Release Date: November 02, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Grifols SA ( NASDAQ:GRFS ) delivered strong Q3 2026 results with group revenue growth of 8.4% at constant currency, driven by biopharma growth of 10.3%.
-
Adjusted EBITDA margin expanded by 60 basis points to 26.4% in Q3, keeping the company on track to meet its full-year 2026 guidance of 25%.
-
Free cash flow before M&A reached nearly 300 million for the first nine months, up 59% year-over-year, supporting deleveraging.
-
Total net leverage declined to just below 4 times, a significant improvement from 5.5 times in June 2024, strengthening the balance sheet.
-
The Board announced an interim dividend of 0.15 per share, reflecting confidence in the company's performance and cash flow generation.
Negative Points
-
Albumin performance remains challenging, with revenues declining 13.2% in Q3 and 13.9% year-to-date due to regulatory restrictions and elevated inventories in China.
-
Diagnostics revenues declined 7% due to the dissolution of the joint business with QuidelOrtho, with the impact expected to continue through the end of 2026.
-
Grifols SA ( NASDAQ:GRFS ) anticipates more modest biopharma growth in Q4 2026, lapping a strong sales quarter from Q4 2025.
-
The company faces increased regulatory scrutiny from European agencies regarding adverse events, which could pose reputational and operational risks.
-
Free cash flow conversion benefited from phasing-related gains that are expected to unwind in Q4 2026, potentially impacting cash flow performance.
Q & A Highlights
Q: On albumin, can you provide further color on the recovery and when channel destocking should reach normalized levels? A: CEO Jose Ignacio Abia Buenache said he does not want to be speculative on China. He was more optimistic a couple of quarters ago that the market would recover in the second half of the year, which has not yet been the case. Sell-through is now at positive but not highly positive levels, which he views as a positive sign, but market inventory remains high and it is difficult to predict competitors' inventory levels. He anticipates more stability in 2027 as comparisons will be against a depressed 2026, but visibility on how fast current inventory will be flushed out remains limited.
Q: On free cash flow, your math suggests 2026 could land at the high end or above the $570 million guidance, leaving roughly $600 million for 2027. How confident are you in these targets? A: CFO Rahul Srinivasan noted that some of the year-to-date phasing benefits will unwind in Q4 2026, but he remains confident about achieving the 2026 free cash flow guidance and the target set out for the period to 2027, agreeing with the analyst's framing.
Q: On phasing, can you reiterate the FY26 sales guide, explain the strong rabies dynamic, and confirm whether there is phasing to account for in IG beyond the tough Q4 comp? A: CFO Rahul Srinivasan guided to modest growth in Q4 2026 versus a very strong Q4 2025, with Q4 2026 expected to be better but only modestly so. He said the same logic translates to IG, so the modest growth expectation can be extrapolated to that franchise.
Q: On the potential US biopharma IPO, when might we hear more, and how progressed is the review versus when it was first announced in Q1? A: CFO Rahul Srinivasan said it is a critical decision for the Board, which is being diligent in its assessment. He does not expect an update on the IPO until 2027, and the company is limited by legal and regulatory constraints on what it can say. He emphasized the clear focus is on unlocking value.
Q: On SPARTA, what is the key benchmark efficacy bar to meet for CT lung density preservation over three years to set expectations for the readout? A: CEO Jose Ignacio Abia Buenache said results are planned to be presented in Q1 2027. SPARTA evaluates efficacy and safety of standard-dose and double-dose Prolastin C versus placebo in emphysema progression over three years, with a primary endpoint of change from baseline in whole-lung PD15 on CT, measuring lung tissue density loss over time. He noted it is not a pharmacokinetic-only study and that the company has no visibility on results so far.
Q: On IG in the second half, is the high end of mid-to-high single-digit growth a good reference, and will the Egypt plasma collection run rate persist into 2027-2028 or be more back-loaded? A: CFO Rahul Srinivasan said the company manages the business annually, not quarterly or semi-annually, and is modulating IG growth alongside albumin market conditions to optimize EBITDA growth and margin improvement rather than chase top-line growth. On Egypt, he said the ramp-up is very small in current gross margin numbers, with a much greater impact expected in 2027 and even more in 2028 and 2029. CEO Jose Ignacio Abia Buenache added that collections are increasing steadily month after month, centers are not yet at peak, and growth should be linear rather than back-loaded, with 18 centers already operating and additional centers to complement them.
Q: On diagnostics, dynamics improved materially this quarter. What specifically happened? A: CEO Jose Ignacio Abia Buenache said the decline versus prior year reflects the absence of QuidelOrtho income, which will be visible through the entire year. The other two pillars, blood typing solutions and NAT testing, are both growing, with the combined business up 2.3%, driven by mid-to-high single-digit growth in blood typing solutions and a couple of percentage points in NAT. He said Grifols is growing with or above the market in many areas where it plays.
Q: On working capital, Q3 inventory building more than offset APK improvement. Should this persist into Q4, and how does it reconcile with objectives to slow growth? A: CFO Rahul Srinivasan said there are no concerns around the conscious investment in inventory, which is entirely consistent with what the company has said on every quarterly call this year. He is not concerned about achieving the full-year free cash flow guidance.
Q: On R&D as a percentage of sales, R&D declined 100 basis points year-on-year in Q3 while capitalized R&D rose 24%. What is driving this change, and is it related to diagnostics following the partnership change? A: CFO Rahul Srinivasan said the increase in capitalized R&D is partly explained by hitting expected milestones on the Mundaka project, which meant the company started capitalizing it. CEO Jose Ignacio Abia Buenache added that Grifols has been rationalizing R&D expenditure, focusing selectively on initiatives believed to move the needle most, protecting must-protect areas while cancelling a number of projects over recent years that could not be seen through.
Q: On Alpha-1 and specialty proteins, Q3 showed double-digit growth. How should we think about Q4 and beyond? A: CFO Rahul Srinivasan reiterated guidance of mid-single-digit growth for the full year 2026 in Alpha-1 and specialty proteins and said the company feels comfortable with that guidance.
Q: On gross margin, nine-month 2026 is already at 38%, the soft guidance for the year. How comfortable are you, and is there upside? A: CFO Rahul Srinivasan noted the reported gross margin contains several moving parts, including headwinds from China albumin, plasma center reorganization, the diagnostics joint business, and Biotest Yimmugo US sales, which are top-line additive but short-term dilutive to gross margin. He pointed to the adjusted metric in the annex and said the company is on track at the 38% benchmark, needing to replicate that level in Q4 to achieve the full-year number.
Q: On increased regulatory scrutiny by
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
